January 13, 2020 / 11:15 AM / 6 months ago

Acasti Pharma's krill oil-derived drug fails late-stage study

Jan 13 (Reuters) - Acasti Pharma Inc said on Monday its krill oil-derived drug candidate, CaPre, was not more effective than placebo in reducing high levels of triglycerides in a late-stage study.

U.S.-listed shares of Acasti were down 54% at $1 before the bell.

The Canada-based drug developer said CaPre failed to show a statistically significant reduction in blood triglycerides compared to placebo after 12 weeks and 26 weeks of treatment.

Triglycerides are a type of fat found in blood that contributes to heart disease alongside cholesterol. (Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below